Chimerix, Inc. (NASDAQ:CMRX) VP David Jakeman Sells 2,800 Shares

Chimerix, Inc. (NASDAQ:CMRX) VP David Jakeman sold 2,800 shares of Chimerix stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $4.10, for a total value of $11,480.00. Following the sale, the vice president now owns 149,287 shares in the company, valued at $612,076.70. This represents a 1.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Chimerix Stock Performance

Shares of NASDAQ:CMRX traded down $0.17 during midday trading on Friday, reaching $3.94. 1,197,343 shares of the company’s stock traded hands, compared to its average volume of 1,423,372. The company has a market cap of $354.36 million, a price-to-earnings ratio of -4.19 and a beta of 0.36. Chimerix, Inc. has a one year low of $0.75 and a one year high of $4.22. The stock has a 50 day moving average of $2.81 and a 200 day moving average of $1.57.

Chimerix (NASDAQ:CMRX) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.02). The firm had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $1.26 million. During the same quarter in the prior year, the firm posted ($0.27) earnings per share. Sell-side analysts predict that Chimerix, Inc. will post -0.99 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Wedbush restated an “outperform” rating and set a $6.00 price target on shares of Chimerix in a research report on Tuesday, December 10th. HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of Chimerix in a report on Monday, December 30th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of CMRX. Marshall Wace LLP bought a new position in shares of Chimerix during the second quarter valued at $137,000. Valeo Financial Advisors LLC lifted its holdings in shares of Chimerix by 566.9% during the third quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 69,505 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in Chimerix by 66.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock valued at $321,000 after acquiring an additional 138,098 shares during the last quarter. Assenagon Asset Management S.A. increased its position in Chimerix by 154.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company’s stock valued at $2,846,000 after acquiring an additional 496,823 shares during the last quarter. Finally, Stoneridge Investment Partners LLC increased its position in Chimerix by 22.5% during the fourth quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company’s stock valued at $154,000 after acquiring an additional 8,134 shares during the last quarter. 45.42% of the stock is owned by institutional investors.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.